{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:45:11Z","timestamp":1790163911886,"version":"4.1.0"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T00:00:00Z","timestamp":1606348800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T00:00:00Z","timestamp":1606348800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI104621"],"award-info":[{"award-number":["AI104621"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI114855"],"award-info":[{"award-number":["AI114855"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI115754"],"award-info":[{"award-number":["AI115754"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["1U19AI135995"],"award-info":[{"award-number":["1U19AI135995"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lassa fever and Ebola are characterized by non-specific initial presentations that can progress to severe multisystem illnesses with high fatality rates. Samples from additional subjects are examined to extend and corroborate biomarkers with prognostic value for these diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Liquid Chromatography Mass Spectrometry metabolomics was used to identify and confirm metabolites disrupted in the blood of Lassa fever and Ebola patients. Authenticated standards are used to confirm the identify of key metabolites.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We confirm prior results by other investigators that the amino acid\n                      <jats:sc>l<\/jats:sc>\n                      -threonine is elevated during Ebola virus infection.\n                      <jats:sc>l<\/jats:sc>\n                      -Threonine is also elevated during Lassa virus infection. We also confirmed that platelet-activating factor (PAF) and molecules with PAF moiety are reduced in the blood of patients with fatal Lassa fever. Similar changes in PAF and PAF-like molecules were not observed in the blood of Ebola patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Metabolomics may provide tools to identify pathways that are differentially affected during viral hemorrhagic fevers and guide development of diagnostics to monitor and predict outcome.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12985-020-01459-y","type":"journal-article","created":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T07:03:40Z","timestamp":1606374220000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Elevated l-threonine is a biomarker for Lassa fever and Ebola"],"prefix":"10.1186","volume":"17","author":[{"given":"Trevor V.","family":"Gale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S.","family":"Schieffelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis M.","family":"Branco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5683-3250","authenticated-orcid":false,"given":"Robert F.","family":"Garry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald S.","family":"Grant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,26]]},"reference":[{"issue":"9","key":"1459_CR1","doi-asserted-by":"publisher","first-page":"e0005943","DOI":"10.1371\/journal.pntd.0005943","volume":"11","author":"TV Gale","year":"2017","unstructured":"Gale TV, Horton TM, Grant DS, Garry RF. Metabolomics analyses identify platelet activating factors and heme breakdown products as Lassa fever biomarkers. PLoS Negl Trop Dis. 2017;11(9):e0005943.","journal-title":"PLoS Negl Trop Dis"},{"issue":"6","key":"1459_CR2","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.chom.2017.10.011","volume":"22","author":"AJ Eisfeld","year":"2017","unstructured":"Eisfeld AJ, Halfmann PJ, Wendler JP, Kyle JE, Burnum-Johnson KE, Peralta Z, Maemura T, Walters KB, Watanabe T, Fukuyama S, et al. Multi-platform \u2019Omics analysis of human Ebola virus disease pathogenesis. Cell Host Microbe. 2017;22(6):817-829.e818.","journal-title":"Cell Host Microbe"},{"issue":"7","key":"1459_CR3","doi-asserted-by":"publisher","first-page":"e40221","DOI":"10.1371\/journal.pone.0040221","volume":"7","author":"J Weiner 3rd","year":"2012","unstructured":"Weiner J 3rd, Parida SK, Maertzdorf J, Black GF, Repsilber D, Telaar A, Mohney RP, Arndt-Sullivan C, Ganoza CA, Fa\u00e9 KC, et al. Biomarkers of inflammation, immunosuppression and stress with active disease are revealed by metabolomic profiling of tuberculosis patients. PLoS ONE. 2012;7(7):e40221.","journal-title":"PLoS ONE"},{"issue":"1","key":"1459_CR4","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s12936-017-1875-z","volume":"16","author":"S Abdelrazig","year":"2017","unstructured":"Abdelrazig S, Ortori CA, Davey G, Deressa W, Mulleta D, Barrett DA, Amberbir A, Fogarty AW. A metabolomic analytical approach permits identification of urinary biomarkers for Plasmodium falciparum infection: a case-control study. Malar J. 2017;16(1):229.","journal-title":"Malar J"},{"issue":"1","key":"1459_CR5","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.antiviral.2007.11.003","volume":"78","author":"SH Khan","year":"2008","unstructured":"Khan SH, Goba A, Chu M, Roth C, Healing T, Marx A, Fair J, Guttieri MC, Ferro P, Imes T, et al. New opportunities for field research on the pathogenesis and treatment of Lassa fever. Antivir Res. 2008;78(1):103\u201315.","journal-title":"Antivir Res"},{"issue":"5","key":"1459_CR6","doi-asserted-by":"publisher","first-page":"999","DOI":"10.4269\/ajtmh.1985.34.999","volume":"34","author":"JV Lange","year":"1985","unstructured":"Lange JV, Mitchell SW, McCormick JB, Walker DH, Evatt BL, Ramsey RR. Kinetic study of platelets and fibrinogen in Lassa virus-infected monkeys and early pathologic events in Mopeia virus-infected monkeys. Am J Trop Med Hyg. 1985;34(5):999\u20131007.","journal-title":"Am J Trop Med Hyg"},{"issue":"4","key":"1459_CR7","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/j.1365-2141.1989.tb04321.x","volume":"72","author":"D Cummins","year":"1989","unstructured":"Cummins D, Fisher-Hoch SP, Walshe KJ, Mackie IJ, McCormick JB, Bennett D, Perez G, Farrar B, Machin SJ. A plasma inhibitor of platelet aggregation in patients with Lassa fever. Br J Haematol. 1989;72(4):543\u20138.","journal-title":"Br J Haematol"},{"key":"1459_CR8","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.cca.2016.06.005","volume":"460","author":"C Fattuoni","year":"2016","unstructured":"Fattuoni C, Palmas F, Noto A, Barberini L, Mussap M, Grapov D, Dess\u00ec A, Casu M, Casanova A, Furione M, et al. Primary HCMV infection in pregnancy from classic data towards metabolomics: an exploratory analysis. Clin Chim Acta Int J Clin Chem. 2016;460:23\u201332.","journal-title":"Clin Chim Acta Int J Clin Chem"},{"key":"1459_CR9","doi-asserted-by":"publisher","first-page":"36833","DOI":"10.1038\/srep36833","volume":"6","author":"J Shrinet","year":"2016","unstructured":"Shrinet J, Shastri JS, Gaind R, Bhavesh NS, Sunil S. Serum metabolomics analysis of patients with chikungunya and dengue mono\/co-infections reveals distinct metabolite signatures in the three disease conditions. Sci Rep. 2016;6:36833.","journal-title":"Sci Rep"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-020-01459-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12985-020-01459-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-020-01459-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T07:31:55Z","timestamp":1606375915000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-020-01459-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,26]]},"references-count":9,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1459"],"URL":"https:\/\/doi.org\/10.1186\/s12985-020-01459-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-88556\/v1","asserted-by":"object"}]},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,26]]},"assertion":[{"value":"2 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Tulane University Institutional Review Board (191330) and the Sierra Leone Ethics and Scientific Research Committee (070716) approved this project.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}},{"value":"JSS, LMB, RFG and DSG are members of the VHFC (\n                      \n                      ). The VHFC is a partnership of academic and industry scientists who are developing diagnostic tests, therapeutic agents, and vaccines for Lassa fever, Ebola, and other severe diseases. Tulane University and its various academic and industry partners have filed US and foreign patent applications on behalf of the consortium for several of these technologies. Technical information may also be kept as trade secrets. If commercial products are developed, consortium members may receive royalties or profits. This does not alter our adherence to all policies of the NIH and <i>Virology Journal<\/i> on sharing data and materials. Financial and non-financial competing interests that the editors consider relevant to the content of the manuscript have been disclosed. RFG and LMB are co-founders of Zalgen. LMB is a Zalgen employee. All other authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"188"}}